Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ACADIA Pharmaceuticals Inc. - Common Stock (NQ:ACAD)

20.93 -0.33 (-1.55%)
Streaming Delayed Price Updated: 12:55 PM EDT, Jun 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about ACADIA Pharmaceuticals Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
ACADIA Pharmaceuticals Spotlights Alzheimer’s Psychosis Pipeline, NUPLAZID and DAYBUE Growth ↗
ACADIA Pharmaceuticals (NASDAQ:ACAD) executives used an RBC Capital Markets investor session to outline the company’s clinical rationale for remlifanserin in Alzheimer’s disease psychosis, provide... 
Via MarketBeat
News headline image
ACADIA Pharmaceuticals Targets $1B Brand Opportunity as Key Neuropsychiatry Data Looms ↗
ACADIA Pharmaceuticals (NASDAQ:ACAD) executives said the company is focused on expanding its two commercial brands while preparing for several clinical data readouts in neuropsychiatric disorders,... 
Via MarketBeat
News headline image
Acadia (ACAD) Q1 2026 Earnings Transcript ↗
Acadia (ACAD) Q1 2026 Earnings Transcript 
Via The Motley Fool
Acadia Pharmaceuticals (NASDAQ:ACAD) Q1 2026 Earnings Miss Sends Stock Lower ↗
Via Chartmill
Topics Earnings
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Surpasses $1 Billion Revenue Milestone in 2025, Beats Q4 EPS Estimates ↗
Via Chartmill
ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) Emerges as a Value Stock with Strong Fundamentals ↗
Via Chartmill
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Shows Strong Growth Momentum and Technical Setup ↗
Via Chartmill
News headline image
Neurocrine Biosciences to Acquire Celeno Therapeutics in Rare Disease Deal
In a move that signals a significant consolidation within the rare endocrine disease market, Neurocrine Biosciences (NASDAQ: NBIX) announced on April 6, 2026, that it has entered into a definitive... 
Via MarketMinute
News headline image
Soleno Therapeutics: A Masterclass in Rare Disease Redemption and the $2.9B Exit
The following feature explores the trajectory of Soleno Therapeutics as of April 7, 2026. Introduction On the morning of April 7, 2026, the biotechnology sector is processing one of the most... 
Via Finterra
Topics Economy Intellectual Property
News headline image
Neurocrine Biosciences to Acquire Soleno Therapeutics in $2.9 Billion Deal as VYKAT™ XR Sales Soar
Shares of Soleno Therapeutics (NASDAQ: SLNO) surged more than 32% in early trading on Monday, April 6, 2026, following the blockbuster announcement that Neurocrine Biosciences (NASDAQ: NBIX) has... 
Via MarketMinute
Topics Intellectual Property
News headline image
Earnings Scheduled For November 5, 2025 ↗
 
Via Benzinga
News headline image
Investment Manager Bets Big on PTCT Stock, Adds 41,000 Shares, According to Recent SEC Filing ↗
PTC Therapeutics develops therapies for rare diseases, with a portfolio spanning commercial products and investigational candidates. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investment Firm Adds Nearly $4 Milllion Worth of DYN Shares, According to Recent SEC Filing ↗
This clinical-stage biotech develops therapies for rare muscle diseases using its proprietary FORCE platform and research-driven approach. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing ↗
This clinical-stage biotech develops antibody therapeutics targeting cancer, with a pipeline focused on oncology and immunotherapy markets. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Aardvark Therapeutics Becomes Next Pharma Player To Quit Prader-Willi Syndrome Drug Development Efforts ↗
The company said that the decision was based on certain cardiac observations made during routine safety monitoring in a healthy volunteer study. 
Via Stocktwits
News headline image
ACADIA (ACAD) Q4 2025 Earnings Call Transcript ↗
ACADIA (ACAD) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year ↗
Praxis Precision Medicines develops therapies for neurological and psychiatric disorders, aiming to address unmet needs in the CNS market. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Fund Bet Nearly $40 Million on GRAIL Last Quarter. The Stock Just Plunged Over 50% ↗
GRAIL develops advanced cancer detection technologies, serving healthcare providers and individuals seeking early diagnostic solutions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
ACAD Stock Slumps 8% After Hours On Hurdle To EU Approval For Genetic Disorder Drug ↗
The company said that the Committee for Medicinal Products for Human Use informed it of a negative trend around its application after an oral explanation recently. 
Via Stocktwits
News headline image
Rhythm Pharmaceuticals Faces Gravity: FDA Delays and Valuation Pressures Cool 2025’s Biotech Darling
As the final trading days of 2025 wind down, Rhythm Pharmaceuticals (Nasdaq: RYTM) finds itself at a critical crossroads. After a meteoric rise that saw the stock gain over 100% through the first three... 
Via MarketMinute
Topics ETFs Economy World Trade
News headline image
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Shows Strong Growth Momentum and Technical Setup for Breakout ↗
ACADIA Pharmaceuticals shows strong earnings momentum and a bullish technical setup, presenting a potential breakout opportunity for growth investors. 
Via Chartmill
News headline image
Acadia Stock Up 59% in a Year — Is a $51 Million New Stake a Bet on a Bigger Rebound? ↗
One fund is quietly buying into ACADIA — just as the company posts one of its strongest quarters in years. 
Via The Motley Fool
News headline image
Healthcare Investor Exits $13 Million Stake STAAR Surgical Stake as Alcon Deal Drama Looms ↗
One specialist investor just walked away from STAAR Surgical entirely—right as uncertainty over a delayed Alcon deal looms. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
PTC Therapeutics Swings to a Profit on $211 Million in Revenue — Is This Why a Major Fund Just Invested $32 Million? ↗
PTC’s turnaround quarter is raising eyebrows—here’s why one major investor just doubled down. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Dyne Therapeutics Stock Down 30% in a Year — So Why Did One Investor Add Nearly 1 Million Shares? ↗
Dyne Therapeutics Stock Down 30% in a Year — So Why Did One Investor Add Nearly 1 Million Shares? 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Shows Strong Growth Momentum and Technical Setup ↗
ACADIA Pharmaceuticals (ACAD) shows strong growth momentum and technical setup, with surging EPS, revenue, and a high technical grade for potential breakout. 
Via Chartmill
News headline image
Why Dyne Therapeutics Stock Was Crushing it This Week ↗
The company has solid potential with its development of drugs targeting muscle disorders. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Beyond The Numbers: 6 Analysts Discuss ACADIA Pharmaceuticals Stock ↗
 
Via Benzinga
News headline image
Acadia (ACAD) Q3 2025 Earnings Call Transcript ↗
Acadia (ACAD) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
ACADIA Pharmaceuticals's Earnings: A Preview ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.